{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:46:13Z","timestamp":1790487973770,"version":"4.1.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.addr.2004.08.007","type":"journal-article","created":{"date-parts":[[2004,9,25]],"date-time":"2004-09-25T03:13:32Z","timestamp":1096082012000},"page":"267-279","source":"Crossref","is-referenced-by-count":116,"title":["Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease"],"prefix":"10.1016","volume":"57","author":[{"given":"Ulrich","family":"Klotz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2004.08.007_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolskiy","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2004.08.007_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0140-6736(02)07284-7","article-title":"Crohn's disease","volume":"359","author":"Shanahan","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2004.08.007_bib3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(02)07499-8","article-title":"Ulcerative colitis","volume":"359","author":"Farrell","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2004.08.007_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/gast.2003.50045","article-title":"The genetics of inflammatory bowel disease","volume":"124","author":"Bonen","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.007_bib5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S1590-8658(03)00213-5","article-title":"Genetics of inflammatory bowel disease. The beginning of the end or the end of the beginning","volume":"35","author":"Annese","year":"2003","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.addr.2004.08.007_bib6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00042737-200306000-00008","article-title":"Crohn's disease: a defensive deficiency syndrome","volume":"15","author":"Fellermann","year":"2003","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"Suppl. 4","key":"10.1016\/j.addr.2004.08.007_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2036.16.s4.1.x","article-title":"Review article: monitoring activity in ulcerative colitis","volume":"16","author":"Rizello","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. 4","key":"10.1016\/j.addr.2004.08.007_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.16.s4.18.x","article-title":"Review article: monitoring the activity of Crohn's disease","volume":"16","author":"Biancone","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2004.08.007_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2036.17.s2.17.x","article-title":"Review article: Crohn's disease: monitoring disease activity","volume":"17","author":"Sostegni","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1572-0241.2000.01940.x","article-title":"A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis","volume":"95","author":"Cohen","year":"2000","journal-title":"Am. J. Gastroenterol."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2004.08.007_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-2036.17.s2.18.x","article-title":"Review article: medical treatment of severe ulcerative colitis","volume":"17","author":"Rizzello","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2004.08.007_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2036.17.s2.22.x","article-title":"Review article: medical treatment of mild to moderately active Crohn's disease","volume":"17","author":"L\u00f6fberg","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2004.08.007_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.17.s2.23.x","article-title":"Review article: medical treatment of moderate to severe Crohn's disease","volume":"17","author":"Scribano","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2004.08.007_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2036.17.s2.20.x","article-title":"Review article: maintenance treatment of Crohn's disease","volume":"17","author":"Biancone","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.addr.2004.08.007_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2036.17.s2.12.x","article-title":"Review article: prevention of postsurgical relapse and recurrence in Crohn's disease","volume":"17","author":"Cottone","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. III","key":"10.1016\/j.addr.2004.08.007_bib16","doi-asserted-by":"crossref","first-page":"iii43","DOI":"10.1136\/gut.50.suppl_3.iii43","article-title":"New steroids and new salicylates in inflammatory bowel disease: a critical appraisal","volume":"50","author":"Campieri","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.007_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00003088-200140100-00003","article-title":"Pharmacokinetic considerations in the treatment of inflammatory bowel disease","volume":"40","author":"Schwab","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2004.08.007_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00042737-200301000-00012","article-title":"Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy","volume":"15","author":"Tursi","year":"2003","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2004.08.007_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1365-2036.1998.00358.x","article-title":"Gastrointestinal pH profiles in patients with inflammatory bowel disease","volume":"12","author":"Press","year":"1988","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib20","first-page":"183","article-title":"Intraluminal pH of the human gastrointestinal tract","volume":"46","author":"Fallingborg","year":"1999","journal-title":"Dan. Med. Bull."},{"key":"10.1016\/j.addr.2004.08.007_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.48.4.571","article-title":"Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs","volume":"48","author":"Nugent","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.007_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1365-2036.1999.00501.x","article-title":"Prevention of postoperative recurrence of Crohn's disease requires adequate mucosal concentrations of mesalazine","volume":"13","author":"Frieri","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/gut.47.3.410","article-title":"Mucosal 5-aminosalicylic acid concentrations inversely correlates with severity of colonic inflammation in patients with ulcerative colitis","volume":"47","author":"Frieri","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.007_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00054725-200108000-00007","article-title":"Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine","volume":"7","author":"Naganuma","year":"2001","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.addr.2004.08.007_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s002280000163","article-title":"The role of aminosalicylates at the beginning of the new millenium in the treatment of chronic inflammatory bowel disease","volume":"56","author":"Klotz","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.007_bib26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1017987229718","article-title":"Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease, A systematic review","volume":"47","author":"Gisbert","year":"2002","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.addr.2004.08.007_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","article-title":"Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis","volume":"123","author":"Pearson","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2004.08.007_bib28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00063-003-1282-9","article-title":"Suspected cases of severe side effects after infliximab (Remicade\u00ae) in Germany","volume":"98","author":"Andus","year":"2003","journal-title":"Med. Klin."},{"key":"10.1016\/j.addr.2004.08.007_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000016897","article-title":"The role of antibiotics in Crohn's disease","volume":"17","author":"Cangemi","year":"1999","journal-title":"Dig. Dis."},{"key":"10.1016\/j.addr.2004.08.007_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11938-003-0020-y","article-title":"Probiotics, irritable bowel syndrome and inflammatory bowel disease","volume":"6","author":"Floch","year":"2003","journal-title":"Curr. Treatm. Opt. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.007_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0950-3528(97)90056-7","article-title":"Innovations in topical therapy","volume":"11","author":"Richter","year":"1997","journal-title":"Bailli\u00e8re's Clin. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.007_bib32","first-page":"33","article-title":"Pharmaceutical approaches to colon targeted drug delivery systems","volume":"6","author":"Chourasia","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2004.08.007_bib33","first-page":"557","article-title":"Salazopyrin, a new sulfanilamide","volume":"110","author":"Svartz","year":"1942","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.addr.2004.08.007_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-198510040-00001","article-title":"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid","volume":"10","author":"Klotz","year":"1985","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2004.08.007_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.5414\/CPP38514","article-title":"Liver and gut mucosa acetylation of mesalazine in healthy volunteers","volume":"38","author":"Vree","year":"2000","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF00542120","article-title":"Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man","volume":"25","author":"Fischer","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.007_bib37","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0140-6736(93)91443-P","article-title":"Negligible excretion of 5-aminosalicylic acid in breast milk","volume":"342","author":"Klotz","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2004.08.007_bib38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/gut.34.5.669","article-title":"Oroileal transit of slow release 5-aminosalicylic acid","volume":"34","author":"Goebell","year":"1993","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.007_bib39","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0016-5085(95)90691-6","article-title":"Delivery and fate of oral mesalamine microgranules within the human small intestine","volume":"108","author":"Layer","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.007_bib40","first-page":"479","article-title":"Intestinal metabolism and transport of 5-aminosalicylate","volume":"27","author":"Zhou","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.addr.2004.08.007_bib41","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1023\/A:1026450326712","article-title":"Mechanisms of transport and structure\u2013permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers","volume":"17","author":"Proudfoot","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2004.08.007_bib42","first-page":"29","article-title":"Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms","volume":"9","author":"Hein","year":"2000","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.addr.2004.08.007_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003495-199856010-00008","volume":"56","author":"Prakash","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2004.08.007_bib44","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2165\/00003495-200262110-00010","article-title":"Balsalazide. A review of its therapeutic use in mild-to-moderate ulcerative colitis","volume":"62","author":"Muijsers","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2004.08.007_bib45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis","volume":"17","author":"Sandborn","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF01046706","article-title":"The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food","volume":"34","author":"Ryde","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.007_bib47","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2165\/00003495-199141040-00009","article-title":"Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease","volume":"41","author":"Wadworth","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2004.08.007_bib48","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/j.1572-0241.2000.02180.x","article-title":"Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis","volume":"95","author":"Marshall","year":"2000","journal-title":"Amer. J. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.007_bib49","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1046\/j.1365-2036.1999.00642.x","article-title":"Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment","volume":"13","author":"Frieri","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. I","key":"10.1016\/j.addr.2004.08.007_bib50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF03042028","article-title":"Pharmacokinetic properties of various preparations of 5-aminosalicylic acid (5-AS) and budesonide","volume":"94","author":"Klotz","year":"1999","journal-title":"Med. Klin."},{"key":"10.1016\/j.addr.2004.08.007_bib51","first-page":"3124","article-title":"Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties","volume":"46","author":"Tromm","year":"1999","journal-title":"Hepato-Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.007_bib52","first-page":"20","article-title":"5-Aminosalicylic acid containing drugs","volume":"47","author":"Christensen","year":"2000","journal-title":"Dan. Med. Bull."},{"key":"10.1016\/j.addr.2004.08.007_bib53","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00003495-199957030-00013","article-title":"Oral delayed-release mesalazine. A review of its use in ulcerative colitis and Crohn's disease","volume":"57","author":"Prakash","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2004.08.007_bib54","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2165\/00003495-200059040-00016","article-title":"Prolonged-released mesalazine. A review of its therapeutic potential in ulcerative colitis and Crohn's disease","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2004.08.007_bib55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200039020-00001","article-title":"Clinical pharmacokinetics of slow release mesalazine","volume":"39","author":"de Vos","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2004.08.007_bib56","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF03044864","article-title":"Release pattern of 5-aminosalicylic acid in human small intestine: importance of galenic preparation","volume":"93","author":"Keller","year":"1998","journal-title":"Med. Klin."},{"key":"10.1016\/j.addr.2004.08.007_bib57","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/gut.31.11.1271","article-title":"Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion","volume":"31","author":"Laursen","year":"1990","journal-title":"Gut"},{"key":"10.1016\/j.addr.2004.08.007_bib58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2125.1992.tb04021.x","article-title":"Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA)","volume":"33","author":"de Mey","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2004.08.007_bib59","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2036.2000.00696.x","article-title":"Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet","volume":"14","author":"Wilding","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib60","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1046\/j.1365-2036.2003.01558.x","article-title":"Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects","volume":"17","author":"Wilding","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib61","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2036.2003.01445.x","article-title":"Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation","volume":"17","author":"Brunner","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib62","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1046\/j.1365-2036.2003.01564.x","article-title":"Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers","volume":"17","author":"Brunner","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jcgh.2003.50006","article-title":"The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine","volume":"1","author":"Kruis","year":"2003","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2004.08.007_bib64","first-page":"229","article-title":"Aminosalicylates in inflammatory bowel disease","author":"Nimmagadda","year":"2002","journal-title":"Clin. Perspect. Gastroenterol."},{"key":"10.1016\/j.addr.2004.08.007_bib65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2036.1993.tb00080.x","article-title":"Review article: topical corticosteroids in inflammatory bowel disease","volume":"7","author":"Mulder","year":"1993","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib66","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-2036.1998.00348.x","article-title":"Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease","volume":"12","author":"Friend","year":"1998","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. 3","key":"10.1016\/j.addr.2004.08.007_bib67","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2036.1997.tb00814.x","article-title":"Review article: drug development in inflammatory bowel disease: budesonide\u2014a model of targeted therapy","volume":"11","author":"Hamadani","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib68","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2165\/00003495-199550050-00006","article-title":"Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease","volume":"50","author":"Spencer","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2004.08.007_bib69","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2165\/00003495-200262150-00015","article-title":"Budesonide (Entocort\u00ae EC Capsules). A review of its therapeutic use in the management of active Crohn's disease in adults","volume":"62","author":"McKeage","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2004.08.007_bib70","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/clpt.1984.71","article-title":"Kinetics of the epimeric glucocorticoid budesonide","volume":"35","author":"Ryrfeldt","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib71","first-page":"137","article-title":"Budesonide is metabolized by cytochrome P4503A (CYP3A4) enzymes in human liver","volume":"23","author":"J\u00f6nsson","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.addr.2004.08.007_bib72","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2036.1994.tb00339.x","article-title":"Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis","volume":"8","author":"Nyman-Pantelidis","year":"1994","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib73","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2036.1993.tb00113.x","article-title":"Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis","volume":"7","author":"Danielsson","year":"1993","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib74","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2036.2003.01431.x","article-title":"Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole","volume":"17","author":"Edsb\u00e4cker","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib75","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2036.2001.00910.x","article-title":"Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease","volume":"15","author":"Lundin","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1365-2036.2003.01386.x","article-title":"Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease","volume":"17","author":"Lundin","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib77","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1067\/mcp.2000.106895","article-title":"Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration","volume":"67","author":"Seideg\u00e5rd","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib78","article-title":"Dose-proportional kinetics of budesonide controlled ileal release (CIR) capsules","author":"Nilsson","year":"1994"},{"key":"10.1016\/j.addr.2004.08.007_bib79","doi-asserted-by":"crossref","first-page":"A885","DOI":"10.1016\/0016-5085(95)27845-1","article-title":"Dose-proportional kinetics of budesonide ileal release capsules","volume":"108","author":"Nilsson","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2004.08.007_bib80","unstructured":"H.W. M\u00f6llmann, G. Hochhaus, Pharmacokinetics and pharmacodynamics of budesonide after oral application of 1\u00d73 mg budesonide as Budenofalk 3 mg capsules to healthy subjects with and without breakfast, Data on file, Dr. Falk Pharma Freiburg\/Germany. (1998)."},{"key":"10.1016\/j.addr.2004.08.007_bib81","unstructured":"H.W. M\u00f6llmann, G. Hochhaus: Pharmacokinetics, Pharmacodynamics of budesonide after oral application of 1\u00d79 mg budesonide as Budenofalk 3 mg capsules to healthy subjects with and without breakfast. Data on file, Dr. Falk Pharma Freiburg\/Germany. (1998)."},{"key":"10.1016\/j.addr.2004.08.007_bib82","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/00042737-200212000-00012","article-title":"Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules","volume":"14","author":"Edsb\u00e4cker","year":"2002","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2004.08.007_bib83","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2036.2003.01426.x","article-title":"A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsule","volume":"17","author":"Edsb\u00e4cker","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib84","series-title":"Topical Steroids in Gastroenterology and Hepatology","first-page":"30","article-title":"Pharmacokinetics after single and multiple oral dosing of budesonide pH-modified-release capsules in patients with distal ulcerative colitis","author":"Pe\u00f1a","year":"2004"},{"key":"10.1016\/j.addr.2004.08.007_bib85","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.2000.00867.x","article-title":"Budesonide in the treatment of Crohn's disease: a meta-analysis","volume":"14","author":"Papi","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib86","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1365-2036.2002.01289.x","article-title":"Systematic review: the effectiveness of budesonide therapy for Crohn's disease","volume":"16","author":"Kane","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib87","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-0773.2002.900401.x","article-title":"Treatment of distal colitis with local anaesthetic agents","volume":"90","author":"Bj\u00f6rck","year":"2002","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.addr.2004.08.007_bib88","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1046\/j.1365-2036.1997.00220.x","article-title":"Nicotine enemas for active ulcerative colitis\u2014a pilot study","volume":"11","author":"Green","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib89","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1046\/j.1365-2036.2001.01120.x","article-title":"Enteric-release glyceryl trinitrate in active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Hawkes","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2004.08.007_bib90","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1056\/NEJMoa013136","article-title":"Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis","volume":"349","author":"Sinha","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2004.08.007_bib91","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/13543784.11.3.365","article-title":"New developments in the treatment of inflammatory bowel disease","volume":"11","author":"Mutlu","year":"2002","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.addr.2004.08.007_bib92","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1358\/dot.1999.35.7.548266","article-title":"Novel oral specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs","volume":"35","author":"Reddy","year":"1999","journal-title":"Drugs Today"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X04001978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X04001978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T11:57:00Z","timestamp":1705233420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X04001978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0169409X04001978"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2004.08.007","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}